Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN

Parasitology Research

Volumn 108, Issue 5, 2011, Pages 1265-1273

  Tafaghodi, Mohsen ^a,c   Khamesipour, Ali ^d   Jaafari, Mahmoud R ^b,c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; LEISHMANIA VACCINE; NANOSPHERE; PHOSPHATE BUFFERED SALINE; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; FOOT PAD; IN VITRO STUDY; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPLEEN CELL; SWELLING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EMULSIONS; FEMALE; FOOT; IMMUNIZATION; LACTIC ACID; LEISHMANIASIS; LEISHMANIASIS VACCINES; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; NANOSPHERES; OLIGODEOXYRIBONUCLEOTIDES; POLYGLYCOLIC ACID;

LEISHMANIA MAJOR; MUS;

EID: 79956217016     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-010-2176-4     Document Type: Article

References (53)

1. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H (2002) Bacterial CPG-DNA and lipopolysaccharides activate toll-like receptors at distinct cellular compartments. Eur J Immunol 32(7):1958-1968 (Pubitemid 34814552)
2. Alimohammadian MH, Khamesipour A, Darabi H, Firooz A, Malekzadeh S, Bahonar A, Dowlati Y, Modabber F (2002) The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. Vaccine 21(3-4):174-180 (Pubitemid 35346811)
3. Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, Correa J (2004) Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against new world cutaneous leishmaniasis. Vaccine 22(9-10):1320-1326 (Pubitemid 38296677)
4. Badiee A, Jaafari MR, Khamesipour A (2007) Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Exp Parasitol 115(2):127-134 (Pubitemid 44820050)
5. Bahar K, Dowlati Y, Shidani B, Alimohammadian MH, Khamesipour A, Ehsasi S, Hashemi-Fesharki R, Ale-Agha S, Modabber F (1996) Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol 14(5):489-495 (Pubitemid 26327742)
6. Barman SP, Lunsford L, Chambers P, Hedley ML (2000) Two methods for quantifying DNA extracted from poly(lactide-coglycolide) microspheres. J Control Release 69(3):337-344
7. Bhowmick S, Ravindran R, Ali N (2007) Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized th1 response. Vaccine 25(35):6544-6556 (Pubitemid 47198915)
8. Cabrera M, Blackwell JM, Castes M, Trujillo D, Convit J, Shaw MA (2000) Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol 22(2):73-79 (Pubitemid 30098807)
9. Coelho EA, Tavares CA, Lima Kde M, Silva CL, Rodrigues JM Jr, Fernandes AP (2006) Mycobacterium HSP65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (leishmania) major infection. Parasitol Res 98(6):568-575
10. De Luca PM, Mayrink W, Alves CR, Coutinho SG, Oliveira MP, Bertho AL, Toledo VP, Costa CA, Genaro O, Mendonca SCF (1999) Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine 17(9-10):1179-1185 (Pubitemid 29132952)
11. Diwan M, Tafaghodi M, Samuel J (2002) Enhancement of immune responses by co-delivery of a CPG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release 85(1-3):247-262 (Pubitemid 35449468)
12. Flynn B, Wang V, Sacks DL, Seder RA, Verthelyi D (2005) Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CPG motifs. Infect Immun 73(8):4948-4954 (Pubitemid 41105652)
13. Follador I, Araujo C, Orge G, Cheng LH, de Carvalho LP, Bacellar O, Almeida RP, Carvalho EM (2002) Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor. Vaccine 20(9-10):1365-1368 (Pubitemid 34131677)
14. Gupta RK, Siber GR (1995) Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 13(14):1263-1276
15. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K et al (2000) A toll-like receptor recognizes bacterial DNA. Nature 408 (6813):740-745 (Pubitemid 32015992)
16. Iborra S, Carrion J, Anderson C, Alonso C, Sacks D, Soto M (2005) Vaccination with the Leishmania infantum acidic ribosomal p0 protein plus CPG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in c57bl/6 mice but does not prevent progressive disease in BALB/c mice. Infect Immun 73 (9):5842-5852 (Pubitemid 41193021)
17. Iborra S, Parody N, Abánades DR, Bonay P, Prates D, Novais FO, Barral-Netto M, Alonso C, Soto M (2008) Vaccination with the Leishmania major ribosomal proteins plus CPG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect 10:1133-1141
18. Jaafari MR, Ghafarian A, Farrokh-Gisour A, Samiei A, Kheiri MT, Mahboudi F, Barkhordari F, Khamesipour A, McMaster WR (2006) Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 24(29-30):5708-5717 (Pubitemid 43928184)
19. Jaafari MR, Badiee A, Khamesipour A, Samiei A, Soroush D, Kheiri MT, Barkhordari F, McMaster WR, Mahboudi F (2007) The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 25(32):6107-6117 (Pubitemid 47077540)
20. Javadian E, Nadim A, Tahvildare-Bidruni G, Assefi V (1976) Epidemiology of cutaneous leishmaniasis in Iran: B. Khorassan part V: report on a focus of zoonotic cutaneous leishmaniasis in Esferayen. Bull Soc Pathol Exot Fil 69(2):140-143
21. Johansen P, Men Y, Merkle HP, Gander B (2000) Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 50(1):129-146 (Pubitemid 30326693)
22. Kamil AA, Khalil EA, Musa AM, Modabber F, Mukhtar MM, Ibrahim ME, Zijlstra EE, Sacks D, Smith PG, Zicker F, El-Hassan AM (2003) Alum-precipitated autoclaved Leishmania major plus Bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 97(3):365-368 (Pubitemid 39185899)
23. Kedzierski L, Zhu Y, Handman E (2006) Leishmania vaccines: progress and problems. Parasitology 133(Suppl):S87-S112 (Pubitemid 46208033)
24. Keshavarz Valian H, Khoshabe Abdollah Kenedy L, Nateghi Rostami M, Miramin Mohammadi A, Khamesipour A (2008) Role of Mycobacterium vaccae in the protection induced by first generation Leishmania vaccine against murine model of leishmaniasis. Parasitol Res 103:21-28
25. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, Ibrahim ME, Kamil AA, Elsheikh M, Babiker A et al (2000) Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356(9241):1565-1569
26. Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, Modabber F (2005) Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23(28):3642-3648 (Pubitemid 40692409)
27. Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F (2006) Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res 123(3):423-438 (Pubitemid 43905580)
28. Krieg AM (1999) Mechanisms and applications of immune stimulatory CPG oligodeoxynucleotides. Biochim Biophys Acta BBA Gene Struct Expr 1489(1):107-116
29. Krieg AM (2002) CPG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760
30. Mauel J (2002) Vaccination against Leishmania infections. Curr Drug Targets Immune Endocr Metabol Disord 2(3):201-226
31. McCluskie MJ, Davis HL (1998) CPG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol (1950) 161(9):4463-4466
32. Mendez S, Tabbara K, Belkaid Y, Bertholet S, Verthelyi D, Klinman D, Seder RA, Sacks DL (2003) Coinjection with CPG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous leishmaniasis but maintains its potency and durability. Infect Immun 71(9):5121-5129 (Pubitemid 37070755)
33. Misra A, Dube A, Srivastava B, Sharma P, Srivastava JK, Katiyar JC, Naik S (2001) Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 19(25-26):3485-3492 (Pubitemid 32710300)
34. Modabber F (1995) Vaccines against leishmaniasis. Ann Trop Med Parasitol 89(Supplement 1):83-88
35. Mohebali M, Khamesipour A, Mobedi I, Zarei Z, Hashemi-Fesharki R (2004) Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr District, I.R. Iran. Vaccine 22(29-30):4097-4100
36. Newman KD, Sosnowski DL, Kwon GS, Samuel J (1998) Delivery of muc1 mucin peptide by poly(D, L-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J Pharm Sci 87(11):1421-1427
37. Newman KD, Elamanchili P, Kwon GS, Samuel J (2002) Uptake of poly(D, L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res 60(3):480-486
38. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, Sharifi I, Khalil EA, Bernal ID, Antunes CM, Kieny MP, Tanner M (2008) First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 26(52):6759-6767
39. Rebelatto MC, Guimond P, Bowersock TL, HogenEsch H (2001) Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet Immunol Immunopathol 83(1-2):93-105 (Pubitemid 32927188)
40. Reiner SL, Locksley RM (1995) The regulation of immunity to Leishmania major. Annu Rev Immunol 13:151-177
41. Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, Davey DF, Davis H, Klinman DM, Coler RN, Sacks DL, Seder RA (2002) Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CPG oligodeoxynucleotides induces long-term memory cd4+ and cd8+ T cell responses and protection against Leishmania major infection. J Exp Med 195 (12):1565-1573 (Pubitemid 34666070)
42. Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2 (11):845-858 (Pubitemid 37328707)
43. Satti IN, Osman HY, Daifalla NS, Younis SA, Khalil EA, Zijlstra EE, El Hassan AM, Ghalib HW (2001) Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 19(15-16):2100-2106
44. Scott P, Pearce E, Natovitz P, Sher A (1987) Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol 139(1):221-227 (Pubitemid 17091788)
45. Shimizu Y, Yamakami K, Gomi T, Nakata M, Asanuma H, Tadakuma T, Kojima N (2003) Protection against Leishmania major infection by oligomannose-coated liposomes. Bioorg Med Chem 11(7):1191-1195 (Pubitemid 36293515)
46. Shimizu Y, Takagi H, Nakayama T, Yamakami K, Tadakuma T, Yokoyama N, Kojima N (2007) Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages. Parasite Immunol 29(5):229-239 (Pubitemid 46596114)
47. Sinha VR, Trehan A (2003) Biodegradable microspheres for protein delivery. J Control Release 90(3):261-280 (Pubitemid 36859959)
48. Tafaghodi M, Sajadi Tabassi SA, Jaafari M-R, Zakavi SR, Momen Nejad M (2004) Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy. Int J Pharm 280:125-135 (Pubitemid 38950910)
49. Tewary P, Pandya J, Mehta J, Sukumaran B, Madhubala R (2004) Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection. FEMS Immunol Med Microbiol 42(2):241-248 (Pubitemid 39208553)
50. Venkataprasad N, Coombes AGA, Singh M, Rohde M, Wilkinson K, Hudecz F, Davis SS, Vordermeier HM (1999) Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine 17(15-16):1814-1819 (Pubitemid 29172349)
51. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM (2002) Cpg oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol (1950) 168(4):1659-1663
52. Waterborg JH (2002) Quantitation of proteins. In: Walker J (ed) The protein protocols handbook, 2nd edn. Humana, New Jersey, pp 3-36
53. Wu W, Weigand L, Belkaid Y, Mendez S (2006) Immunomodulatory effects associated with a live vaccine against Leishmania major containing CPG oligodeoxynucleotides. Eur J Immunol 36 (12):3238-3247 (Pubitemid 44932725)